New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
16:12 EDTRCPTReceptos says Phase 2 study of RPC1063 met primary efficacy endpoint
Receptos announced that the Phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis met the primary endpoint, reduction in MRI brain lesion activity. The overall safety profile of RPC1063 was consistent with the results of prior trials, and continues to support the differentiation of the drug candidate against other oral agents for treatment of RMS on the market or in clinical development.
News For RCPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
06:06 EDTRCPTReceptos 3.6M share Secondary priced at $100.00
The deal size was increased to $360M from $325M. Credit Suisse and Leerink acted as joint book running managers for the offering.
November 18, 2014
12:42 EDTRCPTReceptos volatility at low end of range
Receptos overall option implied volatility of 53 compares to its 8-week average of 61 according to Track Data, suggesting decreasing price movement.
November 17, 2014
16:02 EDTRCPTReceptos files to sell common stock, no amount given
Receptos intends to use the net proceeds received from this offering to fund continued development of its product candidate RPC1063 in ongoing and planned clinical trials for Relapsing Multiple Sclerosis, Ulcerative Colitis and Crohn's Disease, continued development of its in-licensed product candidate RPC4046 in an ongoing clinical trial for Eosinophilic Esophagitis, ongoing preclinical and research programs, and working capital and other general corporate purposes. Credit Suisse Securities and Leerink Partners LLC are acting as joint lead book-running managers for the offering. Evercore Group L.L.C. and BMO Capital Markets Corp. are acting as book-running managers. Wedbush PacGrow Life Sciences and Nomura Securities International, Inc. are acting as co-managers.
10:41 EDTRCPTReceptos 'priced beyond perfection,' may offer shares, TheStreetSweeper says
Subscribe for More Information
10:27 EDTRCPTReceptos mentioned cautiously by TheStreetSweeper
November 12, 2014
07:53 EDTRCPTLeerink to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use